Achillion Pharmaceuticals (ACHN) : Zacks Investment Research ranks Achillion Pharmaceuticals (ACHN) as 2, which is a Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.5, which indicates as a Buy.
Achillion Pharmaceuticals (ACHN) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $17 and the lowest price target forecast is $4. The average forecast of all the analysts is $9.38 and the expected standard deviation is $4.03.
Company shares have received an average consensus rating of Hold for the current week Achillion Pharmaceuticals (NASDAQ:ACHN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.84 and $8.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.04. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.85, notching a gain of 0.57% for the day. The total traded volume was 800,631 . The stock had closed at $8.80 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Fenton Mary Kay, officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, had unloaded 43,500 shares at an average price of $10.08 in a transaction dated on December 28, 2015. The total value of the transaction was worth $438,480.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.